While there has been a slight improvement in the availability of platinum-based chemotherapy agents, most institutions are still facing shortages and “living paycheck to paycheck” with the drugs, a survey revealed.
Shortages of cisplatin and carboplatin have continued at the majority of National Cancer Center Network (NCCN) institutions, according to data from a follow-up survey conducted by NCCN.